Company profile
Invivyd, Inc.
NASDAQ:IVVDBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Ibramvibart | phase3 | — | 2 | active |
| ADINTREVIMAB | phase2_3 | — | 2 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06523153 | phase1 | active_not_recruiting | 2024-08-28 | 2025-05-01 | Invivyd, Inc. | A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants |
| NCT06039449 | phase3 | completed | 2023-09-08 | 2024-11-19 | Invivyd, Inc. | A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2 |
| NCT05791318 | phase1 | completed | 2023-03-28 | 2024-05-08 | Invivyd, Inc. | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants |
| NCT04859517 | phase2_3 | terminated | 2021-04-27 | 2022-11-04 | Invivyd, Inc. | Evaluation of ADG20 for the Prevention of COVID-19 |
| NCT04805671 | phase2_3 | terminated | 2021-07-26 | 2022-02-10 | Invivyd, Inc. | Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19 |
FDA applications (0)
No records yet.